Payment from Gen-Probe Drives Sharp Q2 Revenue Increase for DiagnoCure | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer diagnostics company DiagnoCure's fiscal second-quarter revenues more than tripled, it reported after the close of the market on Wednesday, driven in part by a milestone payment from Gen-Probe.

For the three months ended April 30, Quebec City-based DiagnoCure recorded C$1.1 million (US$1.1 million) in revenues, up from C$310,907 in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.